Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Top 10 Most Recent Blog Posts
Crafting a Winning Business Strategy: The Ultimate Guide
Category: Business Total Views: 64By : Editor Updated: 05-16-2024
Unlocking Stock Price Analysis: 10 Proven Methods for Investors
Category: Stocks Total Views: 66By : Editor Updated: 05-16-2024
Mastering the Market: A Beginner's Guide to Stock Futures
Category: Markets Total Views: 76By : Editor Updated: 05-16-2024
Stock Market Recap: Ups and Downs - May 16, 2024
Category: Markets Total Views: 87By : Editor Updated: 05-16-2024
Morning Market Updates: What to Know - May 16,2024
Category: Stocks Total Views: 168By : Editor Updated: 05-16-2024
Penny Stocks vs. Regular Stocks: Key Investor Insights
Category: Stocks Total Views: 181By : Editor Updated: 05-16-2024
Assessing Risk Tolerance: A Guide for Smart Investors
Category: Investing Total Views: 221By : Editor Updated: 05-16-2024
Finding Undervalued Penny Stocks: Strategies for Success
Category: Stocks Total Views: 220By : Editor Updated: 05-16-2024
Stock Market Recap: Winners and Inflation - May 15, 2024
Category: Stocks Total Views: 181By : Editor Updated: 05-15-2024
Are Meme Stocks Simply Modern Pump and Dumps?
Category: Stocks Total Views: 255By : Editor Updated: 05-15-2024